top of page
1/2
Pioneering Novel
Life-Saving Medicines
for Cardiomyopathies
Our Mission
At Nuevocor, our mission is to transform the treatment of untreatable cardiomyopathies by embracing a mechanobiology-centered approach.
These devastating conditions pose a significant global healthcare challenge, affecting individuals at a relatively young age and can rapidly lead to heart failure. Presently, the only recourse for these patients is a costly and often elusive cardiac transplant.
To address this challenge, we are building global collaborations with leading experts and institutions, accelerating the development of innovative solutions that offer these patients viable alternatives and improved outcomes.
About Us
With global operations across the United States, Europe and Singapore, Nuevocor focuses on treating heart conditions known as cardiomyopathies by addressing their underlying mechanical defects.
Nuevocor’s lead program, NVC-001, is a novel genetic medicine that treats patients suffering from LMNA-related dilated cardiomyopathy, an aggressive, rare disease with no available targeted treatments.
News
10 June 2025
Nuevocor Strengthens Board with Appointment of Thierry Abribat
SINGAPORE, July 7, 2025 /PRNewswire/ -- Nuevocor, a Singapore-headquartered biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, today announced the appointment of Dr. Thierry Abribat to its Board of Directors.
10 June 2025
Nuevocor Announces FDA Clearance of IND for NVC-001 for LMNA-Related Dilated Cardiomyopathy
SINGAPORE and PHILADELPHIA, June 10, 2025 /PRNewswire/ -- Nuevocor, a Singapore-headquartered biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for NVC-001.
bottom of page